400-9696-311 转1
400-9696-311 转3
400-9696-311 转4
400-9696-311 转5
400客服电话
购买数据产品
400-9696-311 转1
定制咨询业务
400-9696-311 转2
数据与AI定制业务
400-9696-311 转3
商务合作及其他问题
400-9696-311 转4
投诉及建议
400-9696-311 转5
ChiCTR-IPR-15006587
结束
替比夫定
化药
替比夫定
2015-05-26
/
乙肝相关肝癌
应用替比夫定抗病毒治疗对乙肝相关肝癌患者术后乙肝病毒再激活及预后影响的随机对照临床研究
应用替比夫定抗病毒治疗对乙肝相关肝癌患者术后乙肝病毒再激活及预后影响的随机对照临床研究
本研究的目的是对应用替比夫定抗病毒治疗预防肝癌患者术后乙肝病毒再激活的有效性进行评价。
随机平行对照
上市后药物
计算机生成随机号
/
东方肝胆外科医院和上海市科委支持
/
100
/
2008-11-01
2015-03-31
/
1. age 18 to 70 years; 2. positive test for Hepatitis B surface antigen (HBsAg) and negative test for antibody to hepatitis C virus (HCV-Ab) or human immunodeficiency virus; 3. serum hepatitis B virus-deoxyribonucleic acid (HBV-DNA) level lower than 2000 IU/ml; 4. Barcelona Clinic Liver Cancer (BCLA) stage 0, A or a solitary tumor with diameter> 5cm; 5. no extrahepatic metastasis; 6. no radiologic evidence of invasion into major portal/hepatic venous branches; 7. good liver function with Child - Pugh Class A and baseline serum alanine aminotransferase (ALT) level< 2 times the upper limit of normal (reference range<40 IU/L), with no history of encephalopathy, ascites refractory to diuretics, esophago-gastric variceal bleeding; 8. good renal function(a serum creatinine level < 133 umol/L); 9. no previous treatment for hepatitis B with nucleoside or nucleotide analogues or both; 10. no treatment with interferon or other immunomodulators within the previous 12 months; 11. a serum amylase or lipase level lower than 1.5 times the upper limit of normal; 12. no previous treatment of HCC; 13. negative resection margin (R0 resection); 14. histopathological result of the resected specimens being HCC. Eligible patients were excluded if they refused to participate.;
请登录查看拒绝参加者;
请登录查看第二军医大学东肝肝胆外科医院
/
兴园化工园区研究院2026-07-19
浙大二院2026-07-19
BioArt2026-07-19
干细胞与外泌体2026-07-19
医药笔记2026-07-19
医药笔记2026-07-19
医麦客2026-07-19
IPO早知道2026-07-18
GLP1减重宝典2026-07-18
良医汇血液肿瘤资讯2026-07-18